Prescription Sedatives. Canadian Centre on Substance Abuse; 2015 July. Available: http://www.ccsa.ca/Resource%20Library/CCSA-Canadian-Drug-Summary-Prescription-Sedatives-2015-en.pdf. Accessed February 29, 2016.
Voyer P, Preville M, Cohen D, Berbiche D, Beland SG. The prevalence of benzodiazepine dependence among community-dwelling older adult users in Quebec according to typical and atypical criteria. Can J Aging. 2010;29(2):205–13.
Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry. 2005;17(3):189–97.
Discontinuation strategies for patients with long-term benzodiazepines use: A review of clinical evidence and guidelines [Internet]. Canadian Agency for Drugs and Technologies in Health; 2015 July. Available: http://www-ncbi-nlm-nih-gov.uml.idm.oclc.org/pubmedhealth/PMH0078914/pdf/PubMedHealth_PMH0078914.pdf. Accessed: March 1, 2016.
Effective interventions to manage symptoms of benzodiazepine withdrawal in seniors. Canadian Centre on Substance Abuse; 2014 November. Available: http://www.ccsa.ca/Resource%20Library/CCSA-Benzodiazepine-Withdrawal-Seniors-Rapid-Review-2014-en.pdf. Accessed: March 1, 2016.
Hogan DB, Maxwell CJ, Fung TS, et al. Canadian Study of Health and Aging. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol. 2003;10(2):72–7.
Olfson M, King M, Shoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136–42.
Esposito E, Barbui C, Patten SB. Patterns of benzodiazepine use in a Canadian population sample. Epidemiologica e Psichiatria Sociale. 2009;18:248–54.
Alessi-Severini S, Bolton JM, Enns MW, et al. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open. 2014;2(4):E208–16.
Alessi-Severini S, Bolton JM, Enns MW, et al. Sustained use of benzodiazepines and escalation to high doses in a Canadian population. Psychiatry Services in Advance 2016:1–7.
Tanguay Bernard M-M, Luc M, Carrier J-D, Fournier L, Duhoux A, Cote E, et al. Patterns of benzodiazepines use in primary care adults with anxiety disorders. Heliyon. 2018;14(7):e00688.
Steinman MA, Kow M, Balicer RD, Shadmi E. Journal of General Internal Medicine 2017’32(8):891–899.
Johnson CF, Frei C, Downes N, McTaggart SA, Akram G. Benzodiazepine and z-hypnotic prescribing for older people in primary care: a cross-sectional population-based study. Br J Gen Pract. 2016;66(647):e410–5.
Pinsker H, Suljaga-Petchel K. Use of benzodiazepines in primary-care geriatric patients. J Am Geriatrics Society. 1984;32(8):595–7.
Vikander B, Koechling UM, Borg S, Tonne U, Hiltunen AJ. Benzodiazepine tapering: a prospective study. Nord J Psychiatry. 2010;64(4):273–82.
Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204(6):471–9.
Cimolai N. Zopiclone: Is it a pharmacologic agent for abuse? Can Fam Physician. 2007;53:3235–2129.
Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173(9):754–61.
Kreipke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1): e000850.
Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27–31.
Hirdes J, Maxwell C, Neutel C. A prospective study of falls after benzodiazepine use: A comparison of new and repeat use. Pharmacoepidemiol Drug Saf. 1997;6(1):27–35.
Collins, R., Jennings, S., Murphy, N., O’Neill, D. Reluctance of older people to discontinue long term benzodiazepines and related hypnotics. Journal of the American Geriatrics Society. June 2010; 58(6).
Kjosavik SR, Ruth S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf. 2009;18(7):572–8.
Cascade E, Kalali AH. Use of benzodiazepines in the treatment of anxiety. Psychiatry (Edgemont). 2008;5(9):21–2.
Pollmann AS, Murphy AL, Bergman, Gardner D. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 2015;16:19.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Canadian Anxiety Guidelines Initiative Group on Behalf of the Anxiety Disorders Association of Canada and McGill University. Canadian clinical practice guidelines for the management of anxiety, postratumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14,S1 (2014).
Takaesu Y, Utsumi T, Okajima I, Shimura A, Kotorii N, et al. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2019;48: 101214.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–49.
Airagnes G, Lemogne C, Renuy A, et al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCES cohort. BMC Public Health. 2019;19:566.
Taipale H, Sarkila H, Tanskanen A, et al. Incidence of and characteristics with long-term benzodiazepine use in Finland. JAMA Netw Open. 2020;3(10): e2019029.
Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc. 2000;48:811–6.
Pollman AS, Murphy AL, Bergman JC, Gardner DM. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol. 2015;16:19.
Lahteenmaki R, Puustinen J, Vahlberg T, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77(6):975–85.
Hadley SK, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind placebo-controlled trial. J Psychopharmacol. 2012;26(4):461–70.
Moroz G, Rosenbaum JF. Efficacy, safety and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled multicenter study using optimized dosages. J Clin Psychiatry. 1999;60(9):604–12.
Martin P, Tamblyn R, Benedetti A, et al. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018;320(18):1889–98.
Navy HJ, Weffaid L, Delate T, et al. Clinical pharmacist intervention to engage older adults in reducing use of alprazolam. Consult Pharm. 2018;33(12):711–22.
Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19–34.
Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807.
Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much medicine in older people? Deprescribing through shared decision making BMJ. 2016;353: i2893.
The College of Physicians and Surgeons of Manitoba. Standard of Practice: Prescribing benzodiazepines and Z-drugs (including zopiclone and other drugs). Effective date: November 1, 2020. Available: https://cpsm.mb.ca/laws-and-policies/standards-of-practice-of-medicine. Accessed November 3, 2020.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.